Financing, Equity Capital Markets

Kaleido Biosciences

02/21
|
$69.4 Million
Piper Sandler served as bookrunner for Kaleido Biosciences, Inc. on a confidentially marketed follow-on offering
Sub-Type
CMFO
Sub-Sector
Biopharma